Princess Margaret Hospital
A study presented at the ESMO Congress shed light on an ADC directed against an immune checkpoint in PD-L1-expressing solid cancers.
The researchers also surveyed treating oncologists about why they decided to change, or not change, the treatment approach.
Researchers Highlight Progress in Head and Neck Cancer MRD at ASCO, but Results Remain Preliminary
Premium
Clinicians said that residual disease tests could be of great benefit to this population, but advancing technologies will still have to prove themselves.
Personalized Residual Disease Assays Show Promise to Overcome Liquid Biopsy Challenges in Sarcomas
Premium
New data presented at the ASCO annual meeting this week showed that tumor-informed assays could detect emerging recurrence ahead of imaging.
Early-Phase Immunotherapy Trial Results Lend Further Support for ctDNA as Surrogate Endpoint
Premium
Researchers from Princess Margaret Cancer Center demonstrated that a decrease in ctDNA within four weeks after immunotherapy treatment was associated with response and survival.
Oct 6, 2021
May 13, 2016